Current price is more than the intrinsic value

Intrinsic value

Stock has been generating better return on equity than bank FD

ROE vs FD rates

Stock doesn't offer attractive dividend returns

Dividend Returns

Good time to consider, as stock is not in overbought zone

Entry point

Stock not in ASM/GSM lists and not a lot of promoter holding is pledged

No Red Flags

With a market valuation of ₹21,667.40 Cr, IPCA Laboratories is a large-cap company that engages in the pharmaceutical industry.

Why do analysts see 40% potential upside for this pharma stock in 6 months?

Motilal Oswal is bullish on IPCA Laboratories recommended buy rating on the stock with a target price of Rs 1000 in its research report dated December 28, 2022.

Buy IPCA Laboratories; target of Rs 1000: Motilal Oswal

Broker’s Call: Ipca Laboratories (Buy)

Based on the open interest future percentage, 81 stocks have seen long unwinding on Wednesday, including Amara Raja Batteries, Ipca Laboratories, City Union Bank, Navin Fluorine International, and Balrampur Chini Mills.

Trade setup for today: Top 15 things to know before the opening bell

Stocks to watch out for today: Just Dial, IRCTC, HDFC, PTC India, IRB Infrastructure Developers, NBCC India, Ipca Laboratories and more

Stocks in news: Just Dial, IRCTC, HDFC, Ipca Labs and more

Ipca laboratories announced that it added 6.53% stake in Trophic Wellness (TWPL) for total consideration of Rs 10.58 crore.

Ipca Labs hikes stake in TWPL

Buzzing stocks: LIC, IRCTC, Dabur, Wipro, Just Dial, NBCC (India), Securekloud Technologies, PTC India, Alembic Pharma, IPCA Lab, Balrampur Chini, Vishwaraj Sugar, Sterling and Wilson Renewable Energy

Stocks that will see action on December 20, 2022

Prabhudas Lilladher recommended accumulate rating on Ipca Laboratories with a target price of Rs 950 in its research report dated November 15, 2022.

Accumulate Ipca Laboratories; target of Rs 950: Prabhudas Lilladher

Choice Equity Broking recommended Neutral rating on Ipca Laboratories with a target price of Rs 908 in its research report dated November 15, 2022.

Neutral Ipca Laboratories; target of Rs 908: Choice Equity Broking

ICICI Direct recommended hold rating on Ipca Laboratories with a target price of Rs 925 in its research report dated November 15, 2022.

Hold Ipca Laboratories; target of Rs 925: ICICI Direct

Manappuram Finance, IPCA Labs, EID Parry, GE Shipping, Container Corporation of India (Concor), ASM Technologies, Ingersoll-Rand, Pearl Global Industries and Morganite Crucible are going ex-dividend today

IPCA Labs, Concor among 9 stocks to go ex-dividend; Siemens results, Vedanta dividend & more

Ipca Laboratories Limited is engaged in pharmaceuticals business. The Company is a manufacturer and supplier of over 10 active pharmaceutical ingredients (APIs).

IPCA Laboratories Ltd

IPCA Laboratories Ltd

Intrinsic value
Intrinsic value is the calculated value of the company and may differ from current stock price. If intrinsic value > current price, price increase is expected in the future to reduce the gap and vice-versa

ROE vs FD rates
Fixed Deposit rate is a virtually risk-free rate where the investor assumes almost no risk on their investment. If stock's long term average ROE is lower than this rate, investors are better off investing the amount in a FD

Dividend Returns
A dividend is the distribution of reward from a portion of company's earnings and is paid to its shareholders. Good dividend returns indicate good health and outlook for the company

Entry point
High demand for a stock increases its price. If the price is pushed up to a level which is not justified, then it's considered to be in the overbought zone, which is not a good time to buy the stock

News & Opinions

Why do analysts see 40% potential upside for this pharma stock in 6 months?

Buy IPCA Laboratories; target of Rs 1000: Motilal Oswal

Broker’s Call: Ipca Laboratories (Buy)

Trade setup for today: Top 15 things to know before the opening bell

Stocks in news: Just Dial, IRCTC, HDFC, Ipca Labs and more

Ipca Labs hikes stake in TWPL

Stocks that will see action on December 20, 2022

IPCA Laboratories Ltd

Intrinsic valueIntrinsic value is the calculated value of the company and may differ from current stock price. If intrinsic value > current price, price increase is expected in the future to reduce the gap and vice-versa

ROE vs FD ratesFixed Deposit rate is a virtually risk-free rate where the investor assumes almost no risk on their investment. If stock's long term average ROE is lower than this rate, investors are better off investing the amount in a FD

Dividend ReturnsA dividend is the distribution of reward from a portion of company's earnings and is paid to its shareholders. Good dividend returns indicate good health and outlook for the company

Entry pointHigh demand for a stock increases its price. If the price is pushed up to a level which is not justified, then it's considered to be in the overbought zone, which is not a good time to buy the stock

News & Opinions

Why do analysts see 40% potential upside for this pharma stock in 6 months?

Buy IPCA Laboratories; target of Rs 1000: Motilal Oswal

Broker’s Call: Ipca Laboratories (Buy)

Trade setup for today: Top 15 things to know before the opening bell

Stocks in news: Just Dial, IRCTC, HDFC, Ipca Labs and more

Ipca Labs hikes stake in TWPL

Stocks that will see action on December 20, 2022

Intrinsic value
Intrinsic value is the calculated value of the company and may differ from current stock price. If intrinsic value > current price, price increase is expected in the future to reduce the gap and vice-versa

ROE vs FD rates
Fixed Deposit rate is a virtually risk-free rate where the investor assumes almost no risk on their investment. If stock's long term average ROE is lower than this rate, investors are better off investing the amount in a FD

Dividend Returns
A dividend is the distribution of reward from a portion of company's earnings and is paid to its shareholders. Good dividend returns indicate good health and outlook for the company

Entry point
High demand for a stock increases its price. If the price is pushed up to a level which is not justified, then it's considered to be in the overbought zone, which is not a good time to buy the stock